Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
NCT06975111 on ClinicalTrials.gov · last registry update 2026-07-21
An unusually large phase 2/phase 3: 200 participants, more than double the 60 typical for the stage. Due to report 31 October 2029, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Epigenetic aging measurements of "PhenoAge". Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2/P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 200
- Started
- 2026-03-01
- Primary completion
- 2029-10-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Epigenetic aging measurements of "PhenoAge"
Conditions studied
Menopause · Menopause Hot Flashes · Menopause Related Conditions · Cardiovascular
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.